iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial

TIGIT Combination Efficacy:
The TIGIT combination therapy developed by iTeos Therapeutics and GSK has shown 30% more tumor shrinkage compared to Jemperli in a Phase 2 clinical trial.

Collaboration Details:
iTeos and GSK have a development and commercialization agreement for EOS-448, an anti-TIGIT monoclonal antibody, which includes a $625 million upfront payment to iTeos and potential milestones and royalty payments.

Clinical Trials:
EOS-448 is being evaluated in various clinical trials, including combinations with pembrolizumab and Inupadenant, to assess safety, tolerability, and anti-tumor activity.

Immuno-Oncology Portfolio:
GSK has a comprehensive portfolio of antibodies targeting the CD226 axis, including TIGIT, CD96, and PVRIG, which are being explored in novel combinations to transform cancer treatment options.

Market Impact:
The collaboration positions iTeos and GSK to play a leading role in the next generation of immuno-oncology therapies, addressing the need for more effective treatments for patients with cancer.